Literature DB >> 10086813

Learning from case reports: diagnostic issues in an epidemiologic study of pancreatic cancer.

M Soler1, M Porta, N Malats, L Guarner, S Costafreda, J M Gubern, E García-Olivares, M Andreu, F X Real.   

Abstract

Epidemiologic studies on exocrine pancreatic cancer show a large heterogeneity in diagnostic criteria applied to define "caseness." Reanalyses conducted after review of diagnostic information have yielded substantially different results than those based on more crude classifications of disease. During a multicenter prospective study on mutations in the K-ras gene in pancreatic and biliary diseases, hospital diagnoses from 602 patients were reviewed by a panel of experts. There were two main motivations to do so: a generic interest for the quality of the diagnostic data, and the anticipation that a firm diagnosis could be needed to assess whether patients whose tumors did not harbor the mutation were true negatives or false negatives. In addition, the review of diagnoses was helpful to minimize tissue misclassification, and it had a high educational value for clinicians and epidemiologists. This article illustrates why and how this was so through a brief presentation of the 10 most significant cases. With respect to selection and classification of subjects, the main issues that studies on pancreatic cancer need to address are the differential diagnosis of exocrine pancreatic cancer and pancreatitis, the differential diagnosis of exocrine pancreatic cancer and other abdominal tumors, and the use of survival as a hallmark of pancreatic cancer. In epidemiologic studies of pancreatic cancer, it is warranted that a panel of experts centrally reviews all the existing diagnostic evidence (cytohistological and other) of all patients, regardless of whether they have cytohistological confirmation and of their hospital discharge diagnosis.

Entities:  

Mesh:

Year:  1998        PMID: 10086813     DOI: 10.1016/s0895-4356(98)00130-9

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  7 in total

1.  Medical conditions in patients with pancreatic and biliary diseases: validity and agreement between data from questionnaires and medical records. PANKRAS II Study Group.

Authors:  M Soler; N Malats; M Porta; E Fernandez; L Guarner; A Maguire; J L Pinõl; J Rifà; A Carrato
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

2.  Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group.

Authors:  M Porta; N Malats; L Guarner; A Carrato; J Rifà; A Salas; J M Corominas; M Andreu; F X Real
Journal:  J Epidemiol Community Health       Date:  1999-11       Impact factor: 3.710

3.  Timing of blood extraction in epidemiologic and proteomic studies: results and proposals from the PANKRAS II Study.

Authors:  Miquel Porta; José Pumarega; Olga Ferrer-Armengou; Tomàs López; Joan Alguacil; Núria Malats; Esteve Fernàndez
Journal:  Eur J Epidemiol       Date:  2007-07-18       Impact factor: 8.082

4.  Validity of the hospital discharge diagnosis in epidemiologic studies of biliopancreatic pathology. PANKRAS II Study Group.

Authors:  M Porta; S Costafreda; N Malats; L Guarner; M Soler; J M Gubern; E García-Olivares; M Andreu; A Salas; J M Corominas; J Alguacil; A Carrato; J Rifà; F X Real
Journal:  Eur J Epidemiol       Date:  2000-06       Impact factor: 8.082

5.  Cystic fibrosis transmembrane regulator (CFTR) DeltaF508 mutation and 5T allele in patients with chronic pancreatitis and exocrine pancreatic cancer. PANKRAS II Study Group.

Authors:  N Malats; T Casals; M Porta; L Guarner; X Estivill; F X Real
Journal:  Gut       Date:  2001-01       Impact factor: 23.059

6.  Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreatic cancer.

Authors:  F X Real; N Malats; G Lesca; M Porta; S Chopin; G M Lenoir; O Sinilnikova
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

7.  Open-access electronic case report journals: the rationale for case report guidelines.

Authors:  Gordon H Sun; Oluseyi Aliu; Rodney A Hayward
Journal:  J Clin Epidemiol       Date:  2013-06-15       Impact factor: 6.437

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.